Management des Cholangiokarzinoms

[1]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[2]  W. Schmiegel,et al.  Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. , 1998, Cancer research.

[3]  S. Hirohashi,et al.  Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. , 1998, Cancer research.

[4]  W. Jochum,et al.  Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. , 2006, Journal of hepatology.

[5]  K. Brown,et al.  Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. , 1996, AJR. American journal of roentgenology.

[6]  R. Parks,et al.  Cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease , 2002, Gut.

[7]  C. Su,et al.  Hepatolithiasis associated with cholangiocarcinoma , 1997, The British journal of surgery.

[8]  Steven C Cunningham,et al.  Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution , 2007, Annals of surgery.

[9]  D. Rattner,et al.  Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. , 1997, Annals of surgery.

[10]  W. Bechstein,et al.  Extended resections for hilar cholangiocarcinoma. , 1999, Annals of surgery.

[11]  S. Isaji,et al.  Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. , 1999, Journal of hepato-biliary-pancreatic surgery.

[12]  Liu Yubin,et al.  Surgical Management and Prognostic Factors of Hilar Cholangiocarcinoma: Experience with 115 Cases in China , 2008, Annals of Surgical Oncology.

[13]  T. Patel,et al.  Involvement of p38 mitogen‐activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line , 2001, Hepatology.

[14]  Manal M. Hassan,et al.  Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Hospital-Based Case–Control Study , 2007, The American Journal of Gastroenterology.

[15]  M. Nagino,et al.  Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. , 2000, Journal of hepato-biliary-pancreatic surgery.

[16]  C. Meyer,et al.  Liver transplantation for cholangiocarcinoma: results in 207 patients. , 2000, Transplantation.

[17]  E. Van Cutsem,et al.  A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. , 2005, European journal of cancer.

[18]  W. Brockelman,et al.  Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. , 1985, Gastroenterology.

[19]  J. Trojan,et al.  Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial , 2008, British Journal of Cancer.

[20]  P. Neuhaus,et al.  Intrahepatic cholangiocarcinoma: indication for transplantation. , 2003, Journal of hepato-biliary-pancreatic surgery.

[21]  P. Cotton,et al.  Randomised trial of endoscopic steriting versus surgical bypass in malignant low bileduct obstruction , 1994, The Lancet.

[22]  Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. , 2000, Cancer research.

[23]  J. Yook,et al.  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Hermann,et al.  Role of radiation after operative palliation in cancer of the proximal bile ducts. , 1991, American journal of surgery.

[25]  A. Tannapfel,et al.  Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival , 2000, Hepatology.

[26]  J. Lunz,et al.  The effect of interleukin-6 (IL-6)/gp130 signalling on biliary epithelial cell growth, in vitro. , 2000, Cytokine.

[27]  T. Therneau,et al.  A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  G. Gores,et al.  Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. , 2004, Journal of hepatology.

[29]  H. Varnholt,et al.  Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma , 2000, The British journal of surgery.

[30]  G. Gores,et al.  Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. , 2007, Gastroenterology.

[31]  J. Seo,et al.  Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. , 2000, American Journal of Clinical Oncology.

[32]  K. Lindor,et al.  Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis , 2004, American Journal of Gastroenterology.

[33]  L. Blumgart,et al.  Outcome of radical surgery in hilar cholangiocarcinoma. , 1990, Surgery.

[34]  Hajime Isomoto,et al.  Interleukin 6 upregulates myeloid cell leukemia‐1 expression through a STAT3 pathway in cholangiocarcinoma cells , 2005, Hepatology.

[35]  M. Ducreux,et al.  Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  H. Kinoshita,et al.  Hepatolithiasis associated with cholangiocarcinoma , 1995, World Journal of Surgery.

[37]  R. Buchert,et al.  FDG PET in the diagnosis of hilar cholangiocarcinoma , 2001, Nuclear medicine communications.

[38]  P. Schein,et al.  5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Yeh,et al.  Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract , 2004, British Journal of Cancer.

[40]  M. D'Angelica,et al.  18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. , 2008, Journal of the American College of Surgeons.

[41]  G. Gores,et al.  The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis , 2005, Digestive Diseases and Sciences.

[42]  U. Mansmann,et al.  Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. , 2003, Gastroenterology.

[43]  M. Kendrick,et al.  Hepatic resection in the treatment of hilar cholangiocarcinoma. , 2006, Advances in surgery.

[44]  S. Shiesh,et al.  The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis. , 2002, Hepato-gastroenterology.

[45]  M. Ducreux,et al.  Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  D. Smith,et al.  Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer , 2005, British Journal of Cancer.

[47]  G. Gores,et al.  Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma , 2005, Annals of surgery.

[48]  Manal M. Hassan,et al.  Phase II Trial of Cisplatin, Interferon α-2b, Doxorubicin, and 5-Fluorouracil for Biliary Tract Cancer , 2001 .

[49]  P. Watanapa,et al.  Liver fluke‐associated cholangiocarcinoma , 2002, The British journal of surgery.

[50]  Randall G. Lee,et al.  Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. , 1998, Journal of the American College of Surgeons.

[51]  J. Cameron,et al.  Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. , 1990, American journal of surgery.

[52]  Marcus Wiedmann,et al.  Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma , 2003, Cancer.

[53]  James S Goydos,et al.  Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. , 1998, Annals of surgery.

[54]  C. Bender,et al.  External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. , 1997, International journal of radiation oncology, biology, physics.

[55]  D. Yoon,et al.  Capecitabine combined with gemcitabine (CapGem) as first‐line treatment in patients with advanced/metastatic biliary tract carcinoma , 2005, Cancer.

[56]  N. Yonemoto,et al.  Chemotherapy in the Treatment of Advanced Gallbladder Cancer , 2004, Oncology.

[57]  P. Morel,et al.  Grasp or Brush for Biliary Sampling at Endoscopic Retrograde Cholangiography? A Blinded Randomized Controlled Trial , 2008, The American Journal of Gastroenterology.

[58]  G. Gores,et al.  Predictors of Disease Recurrence Following Neoadjuvant Chemoradiotherapy and Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma , 2006, Transplantation.

[59]  A. Rahmouni,et al.  Intrahepatic cholangiocarcinoma. Results of aggressive surgical management. , 1995, Archives of surgery.

[60]  T. Patel,et al.  Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. , 2006, Cancer research.

[61]  T. Nagayasu,et al.  Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study , 2004, Journal of Gastroenterology.

[62]  M. Nagino,et al.  Surgical management of hilar cholangiocarcinoma: the Nagoya experience. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[63]  M. Tsuneyoshi,et al.  c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma , 2002, Histopathology.

[64]  K. Lillemoe,et al.  Perihilar Cholangiocarcinoma Postoperative Radiotherapy Does Not Improve Survival , 1995, Annals of surgery.

[65]  M. Filipits,et al.  Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. , 2003, Anticancer research.

[66]  A. Tannapfel,et al.  Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver , 2000, Gut.

[67]  C. Tournigand,et al.  Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  E. Hurt,et al.  The role of IL-6 and STAT3 in inflammation and cancer. , 2005, European journal of cancer.

[69]  D. Bluemke,et al.  MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension. , 2001, AJR. American journal of roentgenology.

[70]  M. Ortner,et al.  Technology Insight: photodynamic therapy for cholangiocarcinoma , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[71]  R. Howard,et al.  Surgical Management of Hilar Cholangiocarcinoma , 2005, Annals of surgery.

[72]  H. Hass,et al.  Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial , 2002, British Journal of Cancer.

[73]  M. Miyazaki,et al.  Cholangiocarcinoma: Recent progress. Part 2: Molecular pathology and treatment , 2002, Journal of gastroenterology and hepatology.

[74]  A. Tannapfel,et al.  Surgical and Palliative Management and Outcome in 184 Patients With Hilar Cholangiocarcinoma: Palliative Photodynamic Therapy Plus Stenting Is Comparable to R1/R2 Resection , 2006, Annals of surgery.

[75]  M. S. Lee,et al.  Prospective Study of the Effectiveness of Percutaneous Transhepatic Photodynamic Therapy for Advanced Bile Duct Cancer and the Role of Intraductal Ultrasonography in Response Assessment , 2005, Endoscopy.

[76]  M. Nagino,et al.  Immunohistochemically Demonstrated Lymph Node Micrometastasis and Prognosis in Patients With Otherwise Node-Negative Hilar Cholangiocarcinoma , 2003, Annals of surgery.

[77]  M. Choti,et al.  Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis , 2007, Journal of Gastrointestinal Surgery.

[78]  Y. Jan,et al.  Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. , 1998, Anti-cancer drugs.

[79]  M. Miyazaki,et al.  Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival , 2002, The British journal of surgery.

[80]  Randall G. Lee,et al.  Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. , 1998, Annals of surgery.

[81]  M. Nagino,et al.  Hepatectomy With Portal Vein Resection for Hilar Cholangiocarcinoma: Audit of 52 Consecutive Cases , 2003, Annals of surgery.

[82]  T. Patel.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.

[83]  H. Bismuth,et al.  Surgical anatomy and anatomical surgery of the liver , 2005, World Journal of Surgery.

[84]  H. Schlitt,et al.  Peripheral hepatojejunostomy as palliative treatment for irresectable malignant tumors of the liver hilum. , 1999, Annals of surgery.

[85]  K. Oldhafer,et al.  Surgical treatment in proximal bile duct cancer. A single-center experience. , 1996, Annals of surgery.

[86]  Randall G. Lee,et al.  Hepatic resection and transplantation for peripheral cholangiocarcinoma. , 1997, Journal of the American College of Surgeons.

[87]  D. Sahani,et al.  What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? , 2006, The oncologist.

[88]  R. Schilsky,et al.  Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma , 2004, Investigational New Drugs.

[89]  K. Boberg,et al.  Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. , 2000, Journal of hepatology.

[90]  J. Furuse,et al.  S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study , 2008, Cancer Chemotherapy and Pharmacology.

[91]  K. Endo,et al.  ERBB‐2 overexpression and cyclooxygenase‐2 up‐regulation in human cholangiocarcinoma and risk conditions , 2002, Hepatology.

[92]  G. Gores,et al.  Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. , 2002, Gastroenterology.

[93]  Abraham Nyska,et al.  Dose-Additive Carcinogenicity of a Defined Mixture of “Dioxin-like Compounds” , 2004, Environmental health perspectives.

[94]  T. Takada,et al.  Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. , 1994, Oncology.

[95]  L. Lepre,et al.  Late Development of Bile Duct Cancer in Patients Who Had Biliary-Enteric Drainage for Benign Disease: A Follow-Up Study of More Than 1,000 Patients , 2001, Annals of surgery.

[96]  M. Nagino,et al.  Lymph Node Metastasis from Hilar Cholangiocarcinoma: Audit of 110 Patients Who Underwent Regional and Paraaortic Node Dissection , 2001, Annals of surgery.

[97]  T. Okusaka,et al.  Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer , 2006, Cancer Chemotherapy and Pharmacology.

[98]  K. Endo,et al.  Cyclooxygenase-2 and ERBB-2 in Cholangiocarcinoma: Potential Therapeutic Targets , 2002, Seminars in liver disease.

[99]  A. Goetz,et al.  Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma. , 2000, Journal of hepatology.

[100]  D. Nagorney,et al.  Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. , 1998, Journal of hepato-biliary-pancreatic surgery.

[101]  K. Tsuneyama,et al.  Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype. , 2006, Pathology, research and practice.

[102]  Y. Jan,et al.  A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. , 2003, Japanese journal of clinical oncology.

[103]  G. Gores,et al.  p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. , 2002, Gastroenterology.

[104]  S. Park,et al.  Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma , 2006, Cancer.

[105]  R. Chapman.  Risk factors for biliary tract carcinogenesis. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  Ali Diba,et al.  Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: A randomized trial , 1988, The British journal of surgery.

[107]  S. Choi,et al.  A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer , 2006, Journal of gastroenterology and hepatology.

[108]  F. Sarkar,et al.  Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[109]  W. Jarnagin,et al.  Surgical management of cholangiocarcinoma. , 2004, Seminars in liver disease.

[110]  A. Bergquist,et al.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. , 2002, Journal of hepatology.

[111]  D. Lu,et al.  Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases. , 2001, AJR. American journal of roentgenology.

[112]  D. Germano,et al.  Chemotherapy with Gemcitabine and Oxaliplatin in Patients with Advanced Biliary Tract Cancer: A Single-Institution Experience , 2008, Oncology.

[113]  S. Thongprasert,et al.  Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  J. Lunz,et al.  Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin a: Comparison of a cholangiocarcinoma cell line with primary cultures of non‐neoplastic biliary epithelial cells , 2000, Hepatology.

[115]  W. Scheithauer.  Review of gemcitabine in biliary tract carcinoma. , 2002, Seminars in oncology.

[116]  T. Miyazaki,et al.  Point mutation of K-ras gene codon 12 in biliary tract tumors. , 1994, Gastroenterology.

[117]  T. Takada,et al.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? , 2002, Cancer.

[118]  S. Alberts,et al.  Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma , 2005, Cancer.

[119]  G. Gores,et al.  Prolonged disease‐free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[120]  Charles M. Miller,et al.  Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. , 2008, Surgery.

[121]  S. Sell,et al.  Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. , 1989, The American journal of pathology.

[122]  O. Farges,et al.  Resection of intrahepatic cholangiocarcinoma: a Western experience. , 1999, Journal of hepato-biliary-pancreatic surgery.

[123]  Michael Gregor,et al.  Serum and bile markers for cholangiocarcinoma. , 2004, Seminars in liver disease.

[124]  T. Gruenberger,et al.  Resection of Hilar Cholangiocarcinomas: Pivotal Prognostic Factors and Impact of Tumor Sclerosis , 2003, World Journal of Surgery.

[125]  A. Watanabe,et al.  Interleukin‐6 functions as an autocrine growth factor in a cholangiocarcinoma cell line , 1994, Journal of gastroenterology and hepatology.

[126]  A. Weaver,et al.  "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. , 1995, Mayo Clinic proceedings.

[127]  W. Scheithauer,et al.  Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[128]  C. Marshall,et al.  Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. , 1991, Cancer research.

[129]  Y. Nimura,et al.  Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus , 1990, World Journal of Surgery.

[130]  G. Gores,et al.  Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[131]  A. Kruse,et al.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. , 1989, Gut.

[132]  K. Lillemoe,et al.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. , 1996, Annals of surgery.

[133]  T. Gruenberger,et al.  p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. , 2004, Anticancer research.

[134]  W. Scheithauer,et al.  Two Consecutive Phase II Studies of 5-Fluorouracil/Leucovorin/Mitomycin C and of Gemcitabine in Patients with Advanced Biliary Cancer , 1999, Oncology.

[135]  H. Miyazato,et al.  Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. , 2002, Hepato-gastroenterology.

[136]  W. Jarnagin,et al.  Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. , 1998, Annals of surgery.

[137]  R. Wasielewski,et al.  Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  M. Gonen,et al.  Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma , 2001, Annals of surgery.

[139]  J. Figueras,et al.  Biliary tract cancers. , 2000, The New England journal of medicine.

[140]  O. Farges,et al.  Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries. , 2002, European journal of gastroenterology & hepatology.

[141]  W. Foley,et al.  The Role of Sonography in Imaging of the Biliary Tract , 2007, Ultrasound quarterly.

[142]  J. Kim,et al.  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[143]  G. Gores,et al.  Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma , 2004, Seminars in liver disease.

[144]  Thierry Ponchon,et al.  Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. , 2003, Gastrointestinal endoscopy.

[145]  S. Pyrhönen,et al.  Epirubicin‐Sequential Methotrexate‐5‐Fluorouracil‐Leucovorin Treatment in Advanced Cancer of the Extrahepatic Biliary System: A Phase II Study , 1994, American journal of clinical oncology.

[146]  T. Hickish,et al.  Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. , 1995, European journal of cancer.

[147]  M. Nagino,et al.  Two Hundred Forty Consecutive Portal Vein Embolizations Before Extended Hepatectomy for Biliary Cancer: Surgical Outcome and Long-term Follow-Up , 2006, Annals of surgery.

[148]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[149]  Steven A Curley,et al.  Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. , 2002, Archives of surgery.

[150]  W. Scheithauer,et al.  Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[151]  M. Omata,et al.  High incidence of ras gene mutation in intrahepatic cholangiocarcinoma , 2010, Cancer.

[152]  M. Miyazaki,et al.  Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? , 1998, Surgery.

[153]  W. H. Kim,et al.  Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[154]  T. Ørntoft,et al.  Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.

[155]  W. Scheithauer,et al.  Treatment and outcome of intrahepatic cholangiocellular carcinoma. , 2005, American journal of surgery.

[156]  G. Gores,et al.  EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. , 2008, Gastrointestinal endoscopy.

[157]  D. Doval,et al.  A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer , 2004, British Journal of Cancer.

[158]  M. Makuuchi,et al.  Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. , 1990, Surgery.

[159]  M. Nagino,et al.  Management of Hilar Cholangiocarcinoma: Comparison of an American and a Japanese Experience , 2000, Annals of surgery.

[160]  H. Ueno,et al.  Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer , 2003, Oncology.

[161]  Harada,et al.  Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma , 1999, Histopathology.

[162]  M. Tempero,et al.  Radiochemotherapy and Transplantation Allow Long‐Term Survival For Nonresectable Hilar Cholangiocarcinoma , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[163]  G. Pond,et al.  Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  G. Gores,et al.  Inhibition of interleukin 6–mediated mitogen‐activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line , 1999, Hepatology.

[165]  K. Halling,et al.  Fluorescence in situ hybridization in diagnostic cytology. , 2007, Human pathology.

[166]  T. Linné,et al.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[167]  T. Gruenberger,et al.  Long-term follow-up of surgically treated gallbladder cancer patients. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[168]  G. D. De Palma,et al.  Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. , 2001, Gastrointestinal endoscopy.

[169]  T. Takada,et al.  Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. , 1998, Hepato-gastroenterology.

[170]  K. McGlynn,et al.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.